Table of contents
- Trial overview
- Who is being studied
- Trial design and phase
- What the trial is measuring
- Trial status and size
Trial overview
The available trial is a study of Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin in adults with uncontrolled asthma.[1] The trial title says it is designed to learn how safe the treatment is and how well it works.[1] The study compares the treatment with placebo, which is an inactive look-alike treatment used for comparison.[1]
Who is being studied
This trial focuses on adults with asthma who remain uncontrolled despite medium to high dose ICS plus LABA.[1] ICS means inhaled corticosteroid, and LABA means long-acting beta agonist; both are standard inhaled asthma medicines.[1] The study also includes people who are at risk of exacerbations, which are asthma flare-ups or worsening symptoms.[1]
The trial does not describe children or people with other conditions in the source data, so the population of interest here is adults with difficult-to-control asthma.[1] This makes the study relevant for patients whose asthma is still not well managed with regular inhaled treatment.[1]
Trial design and phase
The study is an interventional study, which means researchers give a treatment and then measure what happens.[1] It is a Phase 2 trial, a stage that usually looks closely at whether a treatment may work and continues safety checks in a larger group of people.[1] The trial status in the source data is Authorised.[1]
The intervention list shows Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin and a placebo comparison.[1] The source data does not give more details about dosing or treatment schedule, so those details are not included here.[1]
What the trial is measuring
The main outcome is time to first CompEx Asthma event.[1] In simple terms, this measures how long it takes before the first combined asthma worsening event happens.[1] The brief summary says the study aims to compare the effect of Human Igg1 Lambda Fab Fragment Against Thymic Stromal Lymphopoietin with placebo on this outcome in patients at risk of exacerbations.[1]
This kind of endpoint helps researchers see whether the treatment may delay asthma worsening.[1] Because the source data only lists one primary outcome, the article focuses on that main measurement rather than on extra endpoints that are not provided.[1]
Trial status and size
The study has an enrollment of 515 people.[1] That means the trial plans to include 515 participants in total.[1] A larger enrollment can help researchers better understand the treatment effect in the target asthma population.[1]
Because the trial is authorised, it appears to be an active registered study rather than a completed one in the source record.[1] The data provided does not include final results, so this article is limited to the study design, target group, and planned outcome measure.[1]
